Registered title, quoted from ClinicalTrials.gov
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
An open trial on multiple myeloma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05618041, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
14 years to 75 years; sex: all
Registered eligibility fields
Eastern Cooperative Oncology Group (ECOG) score ≤2;
Inclusion criterion 5
Creatinine ≤ 1.5 × ULN;
Inclusion criterion 8
Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN;
Inclusion criterion 11
Active hepatitis (HBV DNA or HCV RNA positive);
Exclusion criterion 6
Human immunodeficiency virus (HIV) infection or syphilis infection;
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05618041, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Sign the informed consent and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of the study as specified in the study procedure sheet;
- Diagnosed as recurrent or refractory lymphoma, leukemia or myeloma;
- Tumor cells express targets for CAR-T cell therapy (results: flow cytometry or Immunohistochemical test confirmation);
- Age 14-75 (including threshold), gender unlimited;
- Eastern Cooperative Oncology Group (ECOG) score ≤2;
- HGB ≥ 70g/L (blood transfusion allowed);
- Liver and kidney functions, heart and lung functions meet the following requirements:
- Creatinine ≤ 1.5 × ULN;
- Left ventricular ejection fraction ≥ 50%;
- Blood oxygen saturation>90%;
- Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN;
- For T cell tumor patients, if tumor cells are detected in peripheral blood during screening, flow cytometry should be used to detect that the tumor cell surface immunophenotype is CD4 and CD8 double negative. If the immunophenotype of peripheral blood tumor cells is not double negative for CD4 and CD8, the condition that the proportion of peripheral blood tumor cells is ≤ 1% shall be met;
- Subjects with pregnancy plans must agree to use contraception before entering the study and after the study lasts for six months; If the subject is pregnant or suspected of being pregnant, the investigator shall be informed immediately;
- The subject or guardian understands and signs the informed consent form;
- Expected survival longer than 3 months.
Exclusion Criteria:
- Severe cardiac insufficiency;
- Have a history of severe lung impairment;
- Complicated with other advanced malignant tumors;
- Complicated with severe or persistent infection that cannot be effectively controlled;
- Complicated with severe autoimmune diseases or congenital immune deficiency;
- Active hepatitis (HBV DNA or HCV RNA positive);
- Human immunodeficiency virus (HIV) infection or syphilis infection;
- Have a history of severe allergy to biological products (including antibiotics);
- If there is a history of hematopoietic stem cell transplantation, it should be no more than 6 months before the patient receives allogeneic hematopoietic stem cell transplantation;
- Subjects who received CAR-T therapy or other gene modified cell therapy before screening;
- Conditions that the investigator believes may increase the risk to the subject or interfere with the outcome of the study.
Quoted from ClinicalTrials.gov, NCT05618041, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05618041, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.